<DOC>
	<DOC>NCT00313781</DOC>
	<brief_summary>To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy</brief_summary>
	<brief_title>Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of metastatic, progressive hormone refractory prostate cancer Adequate bone marrow, liver and kidney function Previous treatment with chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>randomized</keyword>
	<keyword>non-comparative</keyword>
	<keyword>efficacy</keyword>
</DOC>